Posted by Michael Wonder on 05 Feb 2026
Leads Biolabs' GPRC5D/CD3 bispecific T-cell engager LBL-034 earns FDA fast track designation—accelerating launch of potential best in class therapy for relapsed/refractory multiple myeloma
27 January 2026 - Nanjing Leads Biolabs today announced that its key investigational asset LBL-034, a GPRC5D/CD3 bi-specific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary CD3 T-cell engager platform——LeadsBody platform, has been granted fast track designation by the US FDA for the treatment of relapsed/refractory multiple myeloma.
